CSL Limited (ASX) reported a statutory loss for FY26 after recognising substantial Impairment and restructuring charges, while underlying Earnings declined by a smaller amount. Reported net loss after tax was US$2.579 billion, compared with underlying net profit after tax before Amortisation of US$3.098 billion. Management has described FY26 as a reset year and is targeting a return to sustainable growth as the company progresses Leadership changes, operational efficiencies and Investment in its core plasma business.

CSL is a global biotechnology company operating through CSL Behring, CSL Seqirus and CSL Vifor. Its businesses span plasma-derived therapies, influenza vaccines, iron deficiency treatments and other specialty medicines. Earnings are influenced by plasma collection volumes, product demand, Manufacturing efficiency, pricing, reimbursement and competition across major healthcare markets.

Revenue increased while underlying earnings declined

CSL reported FY26 Revenue of US$15.797 billion.

Revenue increased 2% on a reported basis and declined 1% at constant currency.

Underlying NPATA was US$3.098 billion, down 4% as reported and 2% at constant currency.

Underlying NPATA per share was US$6.52 at constant currency, also 2% lower than FY25.

Cash generated from operations was US$3.512 billion.

The result shows that CSL's underlying businesses remained profitable despite the statutory loss, although underlying earnings also declined rather than growing during the year.

Impairments drove the statutory loss

CSL recorded US$5.416 billion of impairments and restructuring charges on a net-of-tax basis.

These charges were the main reason statutory earnings moved into a loss.

Impairments are accounting adjustments that reduce the carrying value of Assets when expected future economic benefits decline.

They do not necessarily represent a matching cash outflow in the period in which they are recognised, but they do indicate that assumptions supporting previous asset values have changed.

The scale of the FY26 write-downs makes future execution particularly important because management will need to demonstrate that the remaining asset base can generate the returns expected from it.

CSL Behring remained the largest business

CSL Behring reported revenue of US$11.387 billion.

Its operating result was US$4.612 billion.

The division remains CSL's largest Business and is centred on plasma-derived therapies, including immunoglobulin products.

Plasma collection volumes, donor economics, manufacturing yields and Demand for immunoglobulin remain central to the division's earnings profile.

For FY27, CSL Behring is expected to deliver mid-single-digit revenue growth.

Within the division, immunoglobulin revenue is expected to grow at a mid-to-high single-digit rate.

The ability to achieve this growth will be one of the main indicators of whether CSL's reset is translating into improved operating performance.

CSL Seqirus faces a slower growth profile

CSL Seqirus reported FY26 revenue of US$2.031 billion and an operating result of US$899 million.

The division is focused mainly on influenza vaccines.

For FY27, CSL Seqirus is expected to deliver low single-digit revenue growth.

Influenza vaccination demand can vary from season to season depending on infection patterns, vaccination uptake and government procurement.

This makes Seqirus more exposed to seasonal and public-health factors than CSL's plasma business.

The division's contribution will therefore depend on both demand and execution across manufacturing and distribution.

CSL Vifor continues to face competitive pressure

CSL Vifor reported revenue of US$2.379 billion and an operating result of US$1.252 billion.

The division remains exposed to generic competition in iron products.

Management has also highlighted the Withdrawal of TAVNEOS in the European Union as a Factor affecting the outlook.

These pressures make CSL Vifor one of the more challenging areas of the group heading into FY27.

Generic competition can affect both pricing and market share, while product withdrawals can reduce expected revenue contributions.

The extent to which other products offset these pressures will influence divisional performance.

FY27 is positioned as a return-to-growth year

Management has indicated that CSL is positioned for a return to sustainable growth.

This outlook is based on expectations for higher revenue in CSL Behring, continued contribution from Seqirus and efforts to manage headwinds in Vifor.

The company is also focused on operational efficiency and more disciplined execution.

These objectives will need to be tested against reported results during FY27.

A return to growth will depend not only on revenue expansion but also on Margin performance, cost control and the absence of further material impairments.

Leadership remains in transition

Gordon Naylor was appointed interim chief executive in February 2026.

He is expected to return to the board once a permanent successor is appointed.

Chairman Dr Brian McNamee is also serving his final term as chair.

Diego Sacristan was appointed Chief Commercial Officer of CSL Behring in May 2026.

These changes mean CSL is navigating both operational and leadership transitions at the same time.

A permanent chief executive appointment will be an important milestone because it will provide greater clarity over longer-term strategy and accountability.

Final Dividend was US$1.62 per share

CSL declared a final dividend of US$1.62 per share.

Combined with the Interim Dividend of US$1.30 per share, the total FY26 dividend was US$2.92 per share.

The dividends were unfranked.

Because CSL declares dividends in US dollars while its shares trade in Australian dollars, the amount ultimately received by Australian shareholders can vary with exchange rates.

The final dividend is payable on 2 October 2026.

Future dividends will depend on earnings, cash generation, Capital requirements and board decisions.

Share buyback and Capital Investment continued

CSL announced a share buyback programme of A$1.15 billion.

Of this amount, A$1.0 billion was completed during FY26.

The company also announced US$1.5 billion of expansion investment at its Kankakee, Illinois plasma manufacturing Facility over five years.

The Kankakee investment is intended to increase manufacturing capacity in the plasma business.

The combination of buybacks, dividends and expansion spending means CSL is allocating capital across Shareholder returns and long-term operational capacity.

The financial return on this investment will depend on future demand, production efficiency and execution.

Plasma demand remains central to the recovery

Demand for plasma-derived therapies is a major driver of CSL's long-term earnings.

Immunoglobulin usage continues across a range of medical conditions, making collection volumes and manufacturing capacity important.

The FY27 guidance for mid-to-high single-digit immunoglobulin growth suggests that CSL expects this part of the business to remain a key contributor.

However, growth also depends on donor collection Economics and the cost of processing plasma into finished products.

Any improvement in operating efficiency could support margins alongside revenue growth.

Key risks for FY27

Execution risk remains central after the scale of FY26 impairments.

Further write-downs could occur if assumptions around asset performance weaken again.

Generic competition remains a pressure for CSL Vifor.

Seqirus remains exposed to seasonal influenza demand.

Plasma donor availability and collection costs can affect CSL Behring's economics.

Regulatory compliance, product quality and patient safety remain important across all divisions.

Supply-chain disruptions, geopolitical conditions and currency movements can also influence reported results.

Cybersecurity and artificial intelligence have also been identified among CSL's material risks.

What to watch next

The first major milestone is payment of the final dividend in October 2026.

The Annual General Meeting later in the month will provide another opportunity for shareholders to hear from management and the board.

A permanent chief executive appointment will be an important governance development.

Operationally, the main measures to watch will be CSL Behring revenue growth, particularly immunoglobulin performance, Seqirus growth and the extent of ongoing pressure within Vifor.

The half-year FY27 result will provide the clearest evidence of whether the reset is producing improved earnings.

CSL's FY26 result reflects a substantial statutory loss caused by impairment and restructuring charges, while the underlying businesses remained profitable but did not grow. FY27 now depends on whether management can convert its reset programme into revenue growth, operating efficiency and more consistent financial performance.